The CRISPR safety reset: what Intellia’s lifted FDA hold really means for one-and-done gene editing
On March 2, 2026, the U.S. Food and Drug Administration
A one-time gene edit for cholesterol: promise, price and the risks we can’t yet see
Early data from a tiny trial suggest that a single
Intellia’s gene-editing drug faces a liver-safety test as Phase 3 trials pause
Standfirst: A hospitalised patient with a Hy’s-law-like profile has forced
AstraZeneca’s $555m Algen bet: why the pharma giant is buying AI-generated targets, not equity
AstraZeneca has inked a deal worth “up to” $555 million
Base & Prime Editing Move from Hype to Timelines: What Hits Patients 2026–2030?
Beyond CRISPR Hype Gene editing has promised to revolutionize medicine,
Gene Editing for Everyone: CRISPRware and the Open-Source Biotech Revolution
CRISPRware Signals a New Era in Democratized Gene Editing In
Cholesterol Rewritten: Verve’s Base Editing Therapy May Disrupt a $20B Market
High cholesterol has long been a silent threat lurking in
A Champion Departs: Peter Marks’ Resignation and Biotech’s Crossroads
When Dr. Peter Marks walked out of the FDA’s headquarters
Tropic Unveils Gene-Edited Non-Browning Bananas to Reduce Food Waste
A New Era for Bananas: The Innovation That Could Change
Illumina’s Market Struggles Deepen as U.S.-China Tensions Escalate
Illumina, a prominent biotech firm specializing in gene-sequencing technology, is
AI-Powered Drug Repurposing by BioXcel Therapeutics Accelerates Development of New Neuropsychiatric Treatments
1. Introduction BioXcel Therapeutics is a biopharmaceutical company leveraging artificial
CRISPR-Cas9 Enhances Rice Yields Without Introducing Foreign DNA
This study explores the use of CRISPR-Cas9 technology to increase
Limula Secures $6.8M Funding to Enhance Cell and Gene Therapy Manufacturing
Limula, an innovative biotech company, recently secured $6.8 million in
Innovative Breakthrough in Genomics: Profluent’s OpenCRISPR-1 Revolutionizes Human Genome Editing
In a groundbreaking achievement, the biotechnology firm Profluent has successfully
MOST POPULAR
